Ultragenyx Pharmaceutical Inc. provided earnings guidance for the year 2022. For the year, company expects Crysvita revenue in the Ultragenyx territories to be between $250 million and $260 million, representing growth of 33% year-over-year at the mid-point of guidance. Dojolvi revenue is estimated to be between $55 million and $65 million, representing growth of 60% year-over-year at the mid-point of guidance in the second year of launch.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.89 USD | -3.05% | +3.37% | -8.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.22% | 3.97B | |
+20.03% | 126B | |
+23.61% | 117B | |
+22.77% | 27.52B | |
-18.07% | 20.87B | |
-14.39% | 17.01B | |
-14.81% | 16.26B | |
+9.78% | 14.56B | |
-46.10% | 15.09B | |
+52.34% | 13.89B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc. Provides Earnings Guidance for the Year 2022